Pemvidutide
An experimental weekly GLP-1 and glucagon dual agonist from Altimmune, mainly studied for fatty liver disease (MASH).
- Evidence
- Ongoing clinical research
- Half-life
- Days
- Sources
- 2 cited
Is pemvidutide FDA-approved?
Investigational. Not FDA-approved.
Overview
In the 24-week IMPACT phase 2b trial in people with MASH, the liver disease resolved in about 52–58% of people on pemvidutide, versus 20% on placebo. It hasn't yet shown a clear effect on liver scarring at that time point.
How it works
GLP-1 action lowers appetite; glucagon action pushes the liver to burn stored fat.
How long does pemvidutide stay in the body?
Long enough for once-weekly shots in trials.
What it's studied for
- Fatty liver disease (MASH)
- Obesity
Reported side effects
- Nausea, vomiting, diarrhea
Related: Eloralintide, Pramlintide, Petrelintide, Setmelanotide.
Sources
The studies and prescribing labels this page is written from.
- Weekly pemvidutide versus placebo for MASH (IMPACT): 24-week phase 2b results. Lancet, 2025 PubMed
- Effect of pemvidutide on MASLD: a randomized trial. J Hepatol, 2025 PubMed
